STOCK TITAN
  1. Home
  2. News
  3. ATNM

Actinium Pharmaceuticals, Inc - ATNM STOCK NEWS

Welcome to our dedicated page for Actinium Pharmaceuticals news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmaceuticals stock.

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) is a New York-based biopharmaceutical company focused on developing innovative targeted radiotherapies for the treatment of advanced cancers. Leveraging its proprietary delivery platform, Actinium utilizes alpha-emitting Actinium-225 and Bismuth-213, as well as certain beta-emitting radiopharmaceuticals, in conjunction with monoclonal antibodies to target and kill cancer cells. The company’s leading product candidate, Iomab™-B, is designed to prepare patients for hematopoietic stem cell transplants (bone marrow transplants) by delivering targeted radiotherapy directly to the bone marrow. Iomab™-B is currently in a pivotal, multicenter Phase 3 clinical study for refractory and relapsed acute myeloid leukemia (AML) patients over the age of 55, focusing on durable complete remission as its primary endpoint.

Actinium's second key program, Actimab-A, is undergoing clinical development in Phase 1/2 trials for newly diagnosed AML patients. This program utilizes Actinium-225 and aims to improve outcomes for patients who have failed existing therapies. Actinium is also involved in numerous partnerships and collaborations, such as with Astellas Pharma, AVEO Oncology/LG Chem Life Sciences, and others, to expand its reach in the realm of radiotherapy for solid tumors.

The company has demonstrated promising results in various studies, including the Phase 3 SIERRA trial for Iomab™-B, which showed significant improvements in survival rates among high-risk AML patients, particularly those with TP53 mutations. Further, Actinium's proprietary cyclotron technology for producing Actinium-225 at commercial scale holds potential for reducing production costs and enhancing supply for clinical and commercial purposes. With a robust pipeline and a strong patent portfolio comprising over 230 patents and applications, Actinium Pharmaceuticals continues to make strides in the field of targeted radiotherapies.

For more information, visit Actinium Pharmaceuticals, Inc.

News

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

Rhea-AI Summary
Actinium Pharmaceuticals, Inc. reports positive Phase 3 SIERRA trial results for Iomab-B in treating r/r AML patients 65+ years at TCT Meetings. Unprecedented 100% BMT access and engraftment with improved long-term survival outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.14%
Tags
clinical trial
-
News

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) highlighted positive results from the Phase 3 SIERRA trial of Iomab-B, showing significant improvements in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B. The trial demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation, leading to complete remissions in over 50% of patients. The company also presented promising data on radiopharmaceutical dosimetry and early results from a Phase 1 study using Iomab-ACT conditioning with CD19 CAR-T therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
News

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) announced that five abstracts have been accepted for presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR. The presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant and CAR-T cellular therapy. Two oral presentations will feature results from the Phase 3 SIERRA trial of Iomab-B, showing improved outcomes for patients with high-risk relapsed/refractory acute myeloid leukemia, including those with a TP53 mutation. The posters will cover topics such as dose-response for durable complete remission and low-dose targeted radioimmunotherapy for patients with relapsed or refractory B-Cell ALL or DLBCL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
none
News

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) announced positive Phase 3 SIERRA trial results for Iomab-B, a targeted radiotherapeutic for relapsed or refractory acute myeloid leukemia (AML) patients with TP53 mutation. The trial showed significantly improved survival, durable complete remission, and doubled median overall survival compared to the control arm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
-
News

Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) highlighted the positive results from the Phase 3 SIERRA trial of Iomab-B and Phase 1 trial of Actimab-A at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH). Iomab-B improved overall survival in patients with TP53 mutation with active, relapsed, or refractory AML, demonstrating a significantly greater median overall survival of 5.49 months compared to 1.66 months in the control arm. Actimab-A in combination with Venetoclax was well-tolerated and achieved complete responses, supporting its continued evaluation in relapsed/refractory AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
-
News

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition

Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) announces that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual ASH Meeting, highlighting the differentiated capabilities of Iomab-B and Actimab-A in improving overall survival in patients with relapsed or refractory AML with a TP53 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
News

Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations

Rhea-AI Summary
Actinium Pharmaceuticals presented data at the Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting, highlighting Actimab-A's ability to target and deplete myeloid-derived suppressor cells (MDSCs) in solid tumors. The data showed that Actimab-A reduced cancer patient-derived MDSCs and restored T cell proliferation and effector function. In addition, Actimab-A significantly depleted MDSCs in tumor-bearing humanized mice. The company believes that Actimab-A has the potential to be used in combination with immunotherapy to enhance antitumor immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
clinical trial
-
News

Actinium Appoints Lynn Bodarky as Chief Business Officer

Rhea-AI Summary
Actinium Pharmaceuticals has appointed Lynn Bodarky as Chief Business Officer to lead the company's business development, licensing, and collaboration activities. Ms. Bodarky brings over 25 years of experience in business development and licensing, having executed transactions totaling over $5 billion in value across oncology, autoimmune, and neurological indications. Actinium is a leader in the development of targeted radiotherapies, with a pipeline of highly differentiated therapies and expertise in alpha-emitter payload Actinium-225. The company has positive Phase 3 data for Iomab-B, a CRADA with the NCI, an NIH grant for Iomab-ACT, and novel preclinical solid tumor data. Actinium aims to leverage Ms. Bodarky's extensive experience to bring their radiotherapeutics to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
management
-
News

Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023

Rhea-AI Summary
Actinium Pharmaceuticals, Inc. will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, from November 6 - 8, 2023 in Munich, Germany. Actinium is developing targeted radiotherapies, including Iomab-B for bone marrow transplant conditioning, which met the primary endpoint in the Phase 3 SIERRA trial. Actinium is also advancing other clinical-stage targeted radiotherapeutics and solid tumor programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
conferences
News

Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial

Rhea-AI Summary
Actinium Pharmaceuticals announced that three abstracts detailing results from the Phase 3 SIERRA trial of Iomab-B in relapsed or refractory acute myeloid leukemia (AML) patients have been accepted for presentation at the ASH conference. The trial showed that AML patients with a TP53 mutation who received Iomab-B and a bone marrow transplant had a median overall survival of 5.49 months compared to 1.66 months in patients who did not receive Iomab-B. Iomab-B also demonstrated similar overall survival outcomes in TP53 negative patients. 24% of patients enrolled in the trial had a TP53 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.5%
Tags
clinical trial

FAQ

What is the current stock price of Actinium Pharmaceuticals (ATNM)?

The current stock price of Actinium Pharmaceuticals (ATNM) is $1.24 as of December 23, 2024.

What is the market cap of Actinium Pharmaceuticals (ATNM)?

The market cap of Actinium Pharmaceuticals (ATNM) is approximately 40.2M.

What is Actinium Pharmaceuticals' primary focus?

Actinium Pharmaceuticals focuses on developing targeted radiotherapies for advanced cancers using its proprietary delivery platform.

What are the main product candidates of Actinium Pharmaceuticals?

The main product candidates are Iomab™-B for hematopoietic stem cell transplant preparation and Actimab-A for newly diagnosed AML patients.

What is unique about Actinium's delivery platform?

Actinium's platform utilizes alpha-emitting Actinium-225 and Bismuth-213, as well as beta-emitting radiopharmaceuticals, combined with monoclonal antibodies to target and kill cancer cells.

What are the recent achievements of Actinium Pharmaceuticals?

Recent achievements include positive results from the Phase 3 SIERRA trial for Iomab™-B, indicating improved survival rates in high-risk AML patients.

Who are some of Actinium Pharmaceuticals' key partners?

Actinium has partnerships with Astellas Pharma, AVEO Oncology/LG Chem Life Sciences, among others, to expand radiotherapy applications in solid tumors.

What are the benefits of Actinium's cyclotron technology?

Actinium's cyclotron technology for Actinium-225 production offers potential cost reductions and enhanced supply for clinical and commercial use.

What is Iomab™-B used for?

Iomab™-B is used to prepare patients for hematopoietic stem cell transplants by delivering targeted radiotherapy to the bone marrow.

What is the significance of the SIERRA trial?

The SIERRA trial demonstrated significant improvements in survival rates for high-risk AML patients, including those with TP53 mutations, using Iomab™-B.

How extensive is Actinium's patent portfolio?

Actinium holds over 230 patents and patent applications, showcasing its extensive intellectual property in targeted radiotherapies.

Where can I find more information about Actinium Pharmaceuticals?

More information can be found on their official website at www.actiniumpharma.com.

Stock ATNM logo
Actinium Pharmaceuticals, Inc

NYSE:ATNM

ATNM Rankings

#4989 Ranked by Market Cap
N/A Ranked by Dividends

ATNM Stock Data

40.24M
30.64M
1.79%
30.11%
4.66%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK